We believe Bria-IMT™ is most effective in HLA – type matched patients
Bria-OTS™ is engineered to express 15 unique HLA types in 4 independent cell lines
Provides matched treatment to greater than 99% of patients with advanced breast cancer
Simple saliva test determines patient HLA type for delivery of personalized off-the-shelf Bria-OTS™ immunotherapy
Each patient will then be treated with the appropriate pre-manufactured Bria-OTS™ formulation
This approach allows personalized treatment without the need for personalized manufacturing. Additionally, it saves time and skips expensive and complicated manufacturing procedures associated with other personalized immunotherapy treatments
BriaCell received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to further develop Bria-OTS™
Ongoing collaboration with the NCI to investigate the Bria-OTS™ mechanism action
BriaCell has secured numerous US and international patents for Bria-OTS™
Similar cell lines in development for prostate cancer (Bria-Pros™), lung cancer (Bria-Lung™), and melanoma (Bria-Mel™) including enhanced ability to activate resting (naïve) T cells
